Granulocyte-Macrophage Colony-Stimulating Factor in Melanoma Immunotherapy

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a haematopoietic cytokine that orchestrates the maturation and activation of dendritic cells and macrophages, thereby bridging innate and adaptive immune responses. In melanoma, a malignancy notable for its antigenicity and proclivity to evade immune surveillance, GM-CSF has been investigated both as a stand-alone therapy and as an immunological adjuvant. Preclinical models have demonstrated that GM-CSF enhances tumour antigen uptake and presentation, promotes the recruitment of effector T cells to the tumour microenvironment and can potentiate vaccine-based approaches. Clinically, recombinant GM-CSF has been evaluated in monotherapy, in combination with peptide or whole-cell vaccines, with checkpoint blockade antibodies and as the transgene in oncolytic viral therapies. Early trials yielded variable outcomes, reflecting complexities in dose scheduling, route of administration and the dual potential of GM-CSF to expand myeloid-derived suppressor cells under certain conditions. Recent innovations include GM-CSF-armed oncolytic viruses that selectively replicate in melanoma cells, releasing cytokine payloads in situ, and combined regimens pairing GM-CSF with CTLA-4 or PD-1 blockade to overcome inhibitory signals within the tumour niche. These strategies aim to exploit the modulatory capacity of GM-CSF to reshape the melanoma microenvironment into one conducive to durable antitumour immunity, with a view to improving response rates and overcoming resistance to current therapies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Granulocyte-Macrophage Colony-Stimulating Factor in Melanoma Immunotherapy publication trend

The graph below shows the total number of articles in granulocyte-macrophage colony-stimulating factor in melanoma immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Granulocyte-macrophage colony-stimulating factor (GM-CSF): A cytokine that drives the differentiation, survival and activation of granulocytes, macrophages and dendritic cells.

Dendritic cell: A professional antigen-presenting cell that captures tumour antigens, processes them and presents peptide fragments to T lymphocytes to initiate adaptive immunity.

Oncolytic immunotherapy: A treatment modality using replication-competent viruses engineered to selectively infect and lyse tumour cells, often armed with immunomodulatory genes such as GM-CSF.

Checkpoint inhibitor: A therapeutic antibody that blocks inhibitory pathways (for example PD-1 or CTLA-4) on T cells, releasing brakes on the immune response against cancer.

Tumour microenvironment: The complex milieu surrounding tumour cells, including immune cells, stromal elements and soluble factors, which can either hinder or support antitumour immunity.

References

1. Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma. Journal for ImmunoTherapy of Cancer (2014).
2. Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma. Cancer Immunology, Immunotherapy (2016).
3. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. Frontiers in Immunology (2021).